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ABSTRACT
Objectives: To determine the prevalence and clinical
features associated with micrographia in Parkinson’s
Disease (PD).
Setting: This study was conducted at a Movement
Disorders clinic located in a Veteran Administration
Hospital.
Participants: PD subjects were included only if they
satisﬁed UK Parkinson’s Disease Society criteria for
diagnosis. Subjects with history of severe tremors,
dystonia, dyskinesia, strokes, peripheral neuropathy
and dementia were excluded.
Design: T h i sw a sac a s e econtrol study where PD
subjects were prospectively enrolled and their
demographics, Hoehn & Yahr stage, Uniﬁed Parkinson’s
Disease Rating Scale and Mini Mental Status
examination (MMSE) scores were recorded. All subjects
were speciﬁcally asked for micrographia on history and
the handwritings were quantitatively documented.
Bradykinesia was determined by history and quantiﬁed
by a ﬁnger tap, Purdue pegboard and a timed walk test.
Similarly, hypophonia was determined by history and
the volume of speech quantiﬁed using a decibel meter.
Controls were enrolled for validation of handwriting test
scores and decibel meter recordings.
Primary outcome measures: Prevalence of
micrographia in the PD cohort and the clinical factors
that correlate with micrographia.
Results: 68 subjects with PD were enrolled (68 men;
mean age 72.3 years). Micrographia was identiﬁed in
63.2% of the cohort on verbal history and in 50% of
the cohort when the handwriting test was used for
ascertainment. Micrographia ascertained on history
correlated signiﬁcantly with disease severity (Hoehn &
Yahr stage), motor impairment (Uniﬁed Parkinson’s
Disease Rating Scale), cognitive impairment (MMSE)
and both bradykinesia and hypophonia determined by
history and quantitative testing. Micrographia on
handwriting test correlated with age (p¼0.02), MMSE
testing (p¼0.04), hypophonia by history (p¼0.01) and
bradykinesia by quantitative testing (p¼0.04).
Conclusion: Micrographia was found in nearly half of
the PD cohort. Disease severity and impaired cognition
were important clinical correlates. Micrographia had a
signiﬁcant relationship with bradykinesia and hypophonia,
suggesting a possible overlap in their pathophysiology.
INTRODUCTION
Micrographia is a clinical feature commonly
associated with Parkinson’s disease (PD). The
literature, however, reveals a paucity of data
on the prevalence and on the clinical char-
acteristics of this potentially disabling disease
manifestation. In one study, an overall prev-
alence of 30% was observed (at any time
during their disease course, with 5%
reporting micrographia as a prodromal
symptom.
1 In questionnaire-based cross-
sectional studies, the prevalence has ranged
from as low as 9%
2 to as high as 75%.
3
Additionally, micrographia has been found to
have a high positive likelihood ratio
45of
being associated with an accurate diagnosis
of PD. The phenomenon of micrographia is
not restricted to PD but has been reported in
Huntington’s disease,
6 amyotrophic lateral
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ARTICLE SUMMARY
Article focus
- In this study, prevalence of micrographia in
Parkinson’s disease (PD) is ascertained and the
relationship of micrographia with bradykinesia
and hypophonia is determined using standard-
ized and quantitative assessment tools.
Key messages
- Micrographia is present in nearly 50%e60%
PD cohort and disease severity and impaired
cognition are important correlates.
- It has signiﬁcant relationship with bradykinesia
and hypophonia.
Strengths and limitations of this study
- Large sample size, systematic assessment
methods.
- This study is a cross-sectional single-visit study,
does not determine the effects of dopaminergic
medications or shed light on the therapeutic
measures.
- The study ﬁnds signiﬁcant correlation of cogni-
tion with micrographia based on MMSE testing
but does not use detailed cognitive assessment
battery.
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Open Access Researchsclerosis
7 and lupus
8 conditions; however, these
studies lack adequate number of patients to draw any
conclusion on the speciﬁcity of the symptom.
Micrographia has been deﬁned as an impairment of
a ﬁne motor skill manifesting mainly as a progressive
reduction in amplitude during a writing task. Micro-
graphia can manifest in two dimensions. Handwriting
may decrease in amplitude as one writes across a single
line or manifest as each line gets added with continued
writing in a paragraph.
9e11
In PD, micrographia has been observed to accompany
both bradykinesia and hypophonia,
2 91 2and it has been
suggested that there is an overlap in the pathophysiology
of micrographia and hypophonia.
13 In this current study,
we sought to study PD patients utilizing systematic
clinical assessments in order to accomplish the following
three aims: (1) to identify the prevalence of micro-
graphia in a large well-characterized PD cohort, (2) to
document the clinical proﬁle of micrographia and (3) to
determine if a correlation exists between micrographia,
bradykinesia or hypophonia.
METHODS
The study was a single-visit study approved by the local
Institutional Review Board, and all subjects gave written
informed consent to participate. Subjects with PD were
enrolled from a movement disorders clinic located in
a veterans adminstration medical centre. PD subjects
using United Kingdom Parkinson’s Disease Society
criteria
14 were included. All PD patients who presented to
the clinic for their regular follow-up visit were approached
on a consecutive basis over a period of 2 years, and those
who consented to participate were enrolled.
Subjects with neurological conditions like stroke and
peripheral neuropathy that could potentially impair the
handwriting assessment were excluded. Subjects with
possibility of atypical parkinsonism, stroke, neuropathy
in hands, h/o of signiﬁcant tremors, dystonia- and
levodopa-induced dyskinesias, and those unable to
provide informed consent (MMSE <18) were all
excluded. Age- and sex-matched control subjects were
enrolled from general neurology clinics, including
headache, seizures, low back pain and other non-basal
ganglia neurological conditions. We speciﬁcally sought
a non-basal ganglia control group that had a neurolog-
ical disease in an effort to create a reasonable compar-
ator group. Demographics of PD subjects (age,
handedness, language preference), disease duration,
L-Dopa dose and disease-speciﬁc assessments such as
modiﬁed Hoehn & Yahr staging and Uniﬁed Parkinson’s
Disease Rating Scale (UPDRS) were used. All subjects
were asked if they had experienced any change in their
mental faculties during the course of PD, and Mini
Mental Status examination (MMSE) scoring was used
during the physical exam. Subjects were studied in the
‘ON’ medication condition that was deﬁned as being on
their regular PD medications and subjectively reporting
their typical ‘on’ response while being examined. Pres-
ence of ‘micrographia’ was ascertained on history.
Subjects were asked if they had speciﬁcally noted
a decrease in size of letters in their handwriting during
the writing task. Handwriting was then documented by
a bedside clinical handwriting test in both PD and
control groups. The handwriting test was designed by us
specially for assessment of micrographia and was vali-
dated among the control group. In this test, subjects
were asked to write the letters ‘p’ and ‘d’ using lower
case in print style and using a standard diameter ball
point pen on a lined paper. They were instructed to do
this 20 times in two separate rows (ﬁgure 1). These 20
trials for each letter were written in blocks, and there
were four such blocks consisting of ﬁve trials each. Time
was not a constraining factor, but subjects were allowed
to lift the pen only at the end of each block. A visual
model was presented at the beginning of the test, and no
practice session for writing was allowed. Auditory cues by
the examiner were allowed. For analysis, trials from the
ﬁrst and last block of the letter ‘d’ were used, and areas
of the 2 blocks were calculated (height 3 width). For
each block, height was calculated as the maximum
Figure 1 (A) Handwriting sample of subject 1 with PD. The
letters ‘p’ and ‘d’ have been written using lower case in print
style, on a lined paper, 20 times in two separate rows. These
20 trials for each letter are written in blocks and there are four
such blocks consisting of ﬁve trials each. H2 and H1 represent
maximum vertical stroke in last and ﬁrst blocks, respectively,
and W2 and W1 represent respective total distance traveled
horizontally for the two blocks; these measurements are for the
letters in the second row. Areas for the last (H23W2) and the
ﬁrst (H13W1) blocks was calculated and an area drop of
$30% (0.7) designated as micrographia and a drop of >50%
as severe micrographia. H23W2/H13W1 <0.7 consistent with
micrographia. H23W2/H13W1 <0.5 consistent with severe
micrographia. (B) Handwriting sample of subject 2 with PD.
Second row letters are more crowded than the ﬁrst, crowding
particularly notable in the last few trials.
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the total distance traveled by the pen horizontally. Areas
were determined for the last and ﬁrst blocks, and ratio of
these areas was calculated; micrographia was deﬁned as
an area drop $30%; a drop of >50% represented severe
micrographia (ﬁgure 1). The investigators (AWS and
SWM) performed this assessment and were not blinded
to the two groups, and the method of testing was
validated among the neurological controls.
Hypophonia was determined by history based on
speciﬁc questioning during interview where subjects
were asked if they experienced a clear reduction in the
volume of their speech. Difﬁculty in speaking such as
stuttering or slurring of words was rejected for the
diagnosis of hypophonia. The volume of speech or
loudness was documented objectively with a decibel
meter. Syllable ‘A’ was spoken as naturally as possible 10
times at 3 s intervals in a quiet room. The loudness of
speech was recorded with the decibel meter being
placed at a set distance of 50 cm from the mouth. A
loudness decline of $10 dB between the ﬁrst and tenth
trials was deﬁned as an objective hypophonia (the
method also validated in controls).
Bradykinesia was ascertained on history by speciﬁcally
asking for problems with slowness in movement
and UPDRS II questions. Quantitative assessment of
bradykinesia was achieved with the help of a ﬁnger tap
task, Purdue Pegboard testing and a standardized timed
motor walk.
13 15 In the ﬁnger tapping task, the subject
was required to tap repetitively on a hard surface using
the index ﬁnger of the right and left hand, done for
each side, for 30 s; the number of taps performed in this
duration was recorded. The pegboard task involved
placement of as many pegs as possible over a 30 s period
and was performed with the right and left hands sepa-
rately and with both hands simultaneously. For the
walking test, subjects walked a distance of 7 m back and
forth as fast as they could, and the time required for
walking including turns was recorded.
15
Statistical analysis
All statistical analyses were conducted using SAS V.9.2
(SAS Institute Inc.). Data were described with plotting of
mean/median for all variables, including age, disease
duration, disease severity on Hoehn & Yahr (H&Y)
staging and on total as well as motor subsection of UPDRS
scale, levodopa (L-DOPA) dose, micrographia deter-
mined by history and handwriting test analysis, hypo-
phonia by history and by decibel meter recordings, scores
on MMSE testing, scores on ﬁnger tap task, Purdue
Pegboard and timed walking test. c
2 Test was used for
comparison of PD and control cohorts with regards to
handwriting test and decibel meter readings. Spearman’s
correlation with respective approximated 95% CIs based
on Fisher’s z-transformation was performed to compare
all of the above variables with micrographia (ﬁgure 2).
Cohen’s Kappa statistic was used to assess the agreement
levels between micrographia and dichotomous variables,
such as handwriting scores (#0.7 or >0.7; a 30% decline)
and hypophonia scores (<10 or $10 dB). All results were
based on two-sided test with p values <0.05 considered
statistically signiﬁcant.
RESULTS
Demographics
Sixty-eight PD subjects were enrolled (all were men, mean
age ¼72.3 years; mean disease duration ¼7.8 years) (see
table 1). Twenty additional subjects were approached;
however, they did not consent for participation.
Seven subjects had disease duration of <3 years, and
six had disease durations >15 years. All but two subjects
were right handed; one of these two was ambidexterous.
In language preference, all except two spoke only
one language and that was English. Their levodopa
equivalents, UPDRS and MMSE assessments are shown
in table 1. There were no subjects noted to have tremors
and dystonia at the time of assessment most likely due to
the fact that subjects were studied on medications.
Figure 2 Forest plot used for demonstration of micrographia
determined by history and its correlation with demographics,
bradykinesia and hypophonia measures. *p<0.05, **p#0.01.
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the time of assessment. In addition, general neurological
exam did not reveal presence of neuropathy or stroke
like deﬁcits.
All controls enrolled were age matched, were men and
like PD subjects were right handed.
Prevalence of micrographia
Micrographia was present in 63.2% of the PD cohort (43
subjects) when subjects were asked on history if their
handwriting had speciﬁcally become small. Nearly 50%
of the PD cohort (35 subjects) demonstrated micro-
graphia when the bedside handwriting test was
performed. There was no control subject who reported
micrographia on history. On c
2 testing, the control
handwriting scores (dichotomized #0.7 or >0.7;
p¼0.0001) differed signiﬁcantly from PD (p¼0.0001).
The sensitivity for the handwriting test was determined
to be ¼0.74 (95% CI: 0.59 to 0.86) and speciﬁcity ¼0.88
(95% CI: 0.68 to 0.97). Cohen’s k established moderate
agreement between micrographia assessment on history
and handwriting tests (0.5, 95% CI ¼ 0.38 to 0.77); 15
PD subjects had a unilateral disease (deﬁned by Hoehn
and Yahr Staging scale) with six having a score of 1 and
nine having a score of 1.5. Eight of these nine subjects
demonstrated micrographia, with the affected side being
the dominant right in all patients.
Assessment of hypophonia and Bradykinesia
Thirty-eight PD subjects (out of 68) reported presence of
hypophonia when speciﬁcally asked on history. Thirty-six
subjects showed a decline of $10 dB when decibel meter
scores were used for determination. Cohen’s k revealed
signiﬁcant correlation between hypophonia assessment
on history and objective assessment (0.85, 95% CI ¼ 0.72
to 0.98). On c
2 testing, there was signiﬁcant difference
between decibel meter scores in PD cohort and controls
(p¼0.0001). There were 54 subjects who reported
bradykinesia when speciﬁcally asked on history. Their
quantitative assessment results are shown in table 1.
Factors affecting micrographia
In the PD cohort, 43 subjects were found to have
micrographia based on history. This group showed
signiﬁcant correlation with overall disease severity and
motor impairment (H&Y, UPDRS total and UPDRS III)
and cognitive impairment determined both by history
and the MMSE testing (p¼0.02 and p¼0.002, respec-
tively; ﬁgure 2). It correlated with bradykinesia (deter-
mined both by history and quantitative testing) and
hypophonia (determined both by history and decibel
meter testing). Figure 2 shows the p values.
Micrographia when identiﬁed based on handwriting
analysis (35 subjects) showed signiﬁcant correlation with
age (p¼0.02), MMSE testing (p¼0.04), hypophonia by
history (p¼0.01) and bradykinesia determined by
Purdue testing for the right hand (p¼0.04) and for both
hands (p¼0.04).
This group with micrographia on handwriting test was
further divided into subgroups with mild and severe
impairment based on criteria described in the Methods
section (area decrease >30% is micrographia and area
decrease >50% deﬁned as severe micrographia). Twenty-
three subjects had mild micrographia, 12 had severe
micrographia and two of these 12 had extreme difﬁculty
in completion of the handwriting test. The subgroup
with severe micrographia revealed a signiﬁcant correla-
tion with H&Y staging, the UPDRS total score (p¼0.003)
and the UPDRS III motor score (p¼0.01), bradykinesia
(p¼0.0001) and hypophonia (p¼0.0001) determined by
history. Severe micrographia also correlated with cogni-
tive impairment assessed by history, MMSE testing and
UPDRS I (p¼0.01).
DISCUSSION
This study offers data on a large cohort of PD and
control patients. Micrographia was identiﬁed in 63.2% of
the PD cohort when subjects were speciﬁcally questioned
for micrographia on history and detected in nearly 50%
of the cohort when bedside handwriting test was used for
quantitative assessment. Disease severity and cognition
were identiﬁed as important factors affecting micro-
graphia, and furthermore, there was a strong correlation
of micrographia with hypophonia and bradykinesia,
suggesting a possible overlap in the pathophysiology.
Previous studies and estimates have been hampered by
methodological issues including small sample sizes and
lack of objective measures. This was a single-visit study
where micrographia was identiﬁed by history and was
established by a quantitative bedside handwriting test.
PD patients with handwriting problems may switch their
writing style from cursive to print in order to maintain
legibility. For simplicity, we therefore utilized only a print
style of writing for the assessment; a hierarchy of tasks
including writing in cursive style, words, phrases,
sentences and paragraphs was not provided to the
Table 1 Clinical characteristics of PD subjects
Mean±SD
Age in years 72.369.5
PD duration in years 7.865.5
H&Y stage 260.8
UPDRS total (on score) 49.3618.8
UPDRS I 3.162.1
UPDRS III 29.169.5
L-DOPA equivalent in milligram 766.66500.5
MMSE 24.862.65
Purdue Pegboard score
Right hand 7.762.9
Left hand 6.863
Bilateral assessment 8.564.1
Finger tap score
Right hand 61.7627.2
Left hand 60630.3
Walk time in seconds 16.567.1
H&Y, Hoehn & Yahr stage; UPDRS, Uniﬁed Parkinson’s Disease
Rating Scale; MMSE, mini mental status examination; PD,
Parkinson’s disease.
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and standardized way. The area of writing covered by the
speciﬁed task was determined, calculated by multiplica-
tion of height and distance. It has been observed that
handwriting seems to decline along subsequent lines as
the writing continues in a paragraph. In this study, we
therefore chose to compare the handwriting sample of
the second line instead of the ﬁrst. In a previous study,
16
micrographia was determined based on the decline of
height proportional to an increase in the length of
writing. We found a similar decline in height of letters;
in addition, we found the letters to be overall smaller
and more crowded as the handwriting task continued,
which is an observation often reported by clinicians.
There was a substantial increase in micrographia when
the last and the ﬁrst blocks in second line were
compared.
We found 12 PD subjects with severe micrographia and
two out of these 12 could barely complete the hand-
writing test. The handwriting capacity for these two
subjects was noted to be signiﬁcantly diminished and
almost illegible even at the time of signing the consent
form and on the item of writing a sentence for the
MMSE test. These two subjects were assessed at the time
when their dopaminergic medications had begun to
wear off. Besides, a possibility of underlying apraxia for
writing cannot be ruled out, but we did not speciﬁcally
test for limb-kinetic or ideomotor apraxia.
Handwriting assessment can be potentially marred by
the presence of dystonia, tremors, dyskinesias, history of
stroke and peripheral neuropathy affecting the hand.
These factors were speciﬁcally excluded for the PD
subjects though we did not exclude limb apraxia, hand
injuries, arthritis of neck and hand joints. These factors
should be considered too and excluded for future studies.
The subjects who participated in the study were all
men and veterans. They were enrolled from a tertiary
care centre, and their handwritings were determined by
unblinded raters. These factors may have introduced
a selection and assessment bias in the methods.
It has been suggested that L-DOPA may partially
improve micrographia, but this notion remains to be
veriﬁed. L-DOPA seems to improve writing speed more
than the size
17 and affects the amplitude of the pre-
movement EEG potential (Bereitschaft potential) which is
abnormal in PD.
18 Dopaminergic medication also
increases striatal-frontal connectivity between the caudate
nucleus and prefrontal cortex during motor timing.
19
These results suggest that L-DOPA effects on handwriting
occur possibly at the level of motor programming. In this
study, subjects were studied on medications, and no
correlation was found for micrographia and L-DOPA
equivalent dose. A study on and off medications is deﬁ-
nitely required to provide further insight.
In literature, micrographia has been reported to be
more frequent in native than secondary languages,
owing to impaired execution of more utilized tasks.
20 In
our population, most subjects spoke only one language
(English). We had only two veterans who were ﬂuent in
more than one language (they knew English and Viet-
namese); therefore, in this study, we suspect that the true
effects of language on micrographia could not be
discerned as the sample size of multilingual subjects
was small.
There was also a possible confound of handedness on
the clinical manifestation of micrographia, which has
been proposed to be more frequent in those with left
hemispheric lesions.
21 In our sample, all subjects except
two were right handed (one of them was ambidex-
terous). Due to the homogeneity in the cohort, the
effects of handedness could not be determined.
Although handwriting assessment was performed using
only the dominant hand, presence of micrographia
showed positive correlation with bradykinesia scores
determined for both sides (Purdue pegboard and ﬁnger
tap scores). It would therefore be interesting to deter-
mine if handwriting performance was affected bilaterally
that was something not focused on in this study.
Presence of micrographia did not reveal any statistical
correlation with the overall disease duration though there
was a correlation with disease severity determined on H&Y
staging
22 and UPDRS motor assessments. It is also
important to note that most subjects were unable to recall
the exact onset of timing for handwriting impairment.
Thus, a longitudinal follow-up of these patients will be
required to determine the effects of disease progression.
The effects of external cues on the task of handwriting
in PD are not clear from literature. One study demon-
strated micrographia to get better in the presence of both
visualaswellas auditory cues
23; incontradistinction, Ondo
and Satija
16 found handwriting to get larger when the
subjects performed the handwriting task with eyes closed.
We decided to keep the task simple and allowed both
visual and auditory cues to be providedduring the bedside
handwriting test. The handwriting test was conducted on
lined paper, and a visual model was presented at the
beginning of the task. Auditory announcements for task
commencement and task conclusion weremade; although
unlike the previous study,
23 no speciﬁc reminder to keep
handwriting big was provided.
It has been observed that there is a signiﬁcant inﬂu-
ence of mental load on micrographia
24 and increased
processing demands within the writing task contribute to
reduction in writing size.
25 In this study, although the
mental load was kept at a minimum during the hand-
writing test and a hierarchy of tasks was not tested, we
found those with reports of cognitive impairment on
history and also with lower scores on MMSE testing
showed a correlation with micrographia. We found that
the MMSE scores in this cohort were lower than what
one could expect for the H&Y scores recorded. This was
very intriguing, and we think that there could be
multiple factors contributing. The study was performed
in an older population, we did not record the educa-
tional backgrounds of participants, their medication
records were not reviewed and a detailed cognitive
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testing in PD serves only as a screening tool and does not
capture all aspects of cognitive functioning.
In this cohort, micrographia revealed a signiﬁcant
correlation with both bradykinesia and hypophonia.
Inappropriate scaling of the dynamic muscle force to the
movement parameters has been proposed to be one of
the underlying mechanisms for bradykinesia
26 and
handwriting issues have been found to be more apparent
when a sustained ramp force is required over the dura-
tion of a writing stroke.
27 Similarly, inappropriate scaling
of laryngeal muscles during speech that results from
a hypometric output sent by motorepremotor cortex is
the underlying basis of hypophonia in PD. PET studies
have found abnormal patterns of activation in motore
premotor cortex that may be inﬂuenced by Lee
Silverman Voice therapy, with activation pattern shifting
to basal ganglia and insula.
28 Based on the weight of the
evidence, one could hypothesize that micrographia
similar to bradykinesia and hypophonia is probably due
to a hypometric output driven by motorepremotor
cortex with defects in execution of handwriting instruc-
tions (inappropriate scaling) and that this may explain
the link to bradykinesia and hypophonia.
Future studies of PD-related micrographia should
be directed towards functional imaging and electro-
physiological assessment of the cerebral cortex and its
basal ganglia connections and the on/off effects of
dopaminergic medications. This study is the largest of
its kind in the area of micrographia and it will help
practitioners to understand that the issue is present in
about half of all PD patients and that disease severity,
cognitive impairment, bradykinesia and hypophonia all
seem to be correlated, suggesting an overlap in the
pathophysiology.
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